Bempedoic Acid Pregnancy Surveillance Program

Esperion Therapeutics

Status: Enrolling

Conditions: Hyperlipidemias; Pregnancy

Treatments: Drug: Bempedoic Acid / Ezetimibe; Drug: Bempedoic Acid

Study type: Observational

Funder types: Industry

Identifiers

NCT05103254

1002-074

Details and patient eligibility

About

Bempedoic acid pregnancy surveillance program

Full description

A surveillance study of females exposed to bempedoic acid or bempedoic acid/ezetimibe fixed combination drug product (FCDP) during pregnancy. Observational outcome data will be collected on pregnant females through pregnancy and infants through the first year of life.

Enrollment: 20 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Exposure to at least 1 dose of bempedoic acid or bempedoic acid/ezetimibe FCDP at any time during pregnancy (from first day of last menstrual period [LMP] to pregnancy outcome

Exclusion Criteria: